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Molecular Biology, Cambridge CB2 0QH, UKThe therapeutic effects of gene therapy using adeno-associated
virus (AAV) vectors are dependent on the efficacy of viral trans-
duction. Currently, we have reached the safe limits of AAV vec-
tor dose, beyond which damaging inflammatory responses are
seen. To improve the efficacy of AAV transduction, we treated
mouse embryonic fibroblasts, primate retinal pigment epithe-
lial cells, and human retinal explants with hydroxychloroquine
(HCQ) 1 h prior to transduction with an AAV2 vector encoding
GFP driven by a ubiquitous CAG promoter. This led to
a consistent increase in GFP expression, up to 3-fold,
compared with vector alone. Comparing subretinal injections
of AAV2.CAG.GFP vector alone versus co-injection with
18.75 mM HCQ in paired eyes in mice, mean GFP expression
was 4.6-fold higher in retinae co-treated with HCQ without
retinal toxicity. A comparative 5.9-fold effect was seen with
an AAV8(Y733F).GRK1.GFP vector containing the photore-
ceptor-specific rhodopsin kinase promoter. While the mecha-
nism of action remains to be fully elucidated, our data suggest
that a single pulse of adjunctive HCQ could safely improve
AAV transduction in vivo, thus providing a novel strategy for
enhancing the clinical effects of gene therapy.Received 9 October 2018; accepted 20 May 2019;
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Gene therapies based on adeno-associated virus (AAV) vector-medi-
ated gene transfer are at advanced stages of clinical development to
treat a broad range of monogenic disorders, including inherited
retinal dystrophies,1–4 hemophilia B,5 hemophilia A,6 muscular dys-
trophies,7 and inherited neurodegenerations.8 The approval of vore-
tigene neparvovec by the US Food and Drug Administration (FDA)
for the treatment of Leber congenital amaurosis caused by mutations
in RPE65 has paved the way for similar AAV-based gene therapies in
the near future.9 Recombinant AAV vectors are considered ideal ve-
hicles for transgene delivery compared with lentiviral or adenoviral
vectors due to their low immunogenicity; broad tissue tropism; and
the ability of the delivered therapeutic transgenes to persist as epi-
somes, which carry low mutagenic potential while allowing sustained
transgene expression.Molecular Therapy: Methods & Clin
This is an open access article underThe clinical efficacy of AAV-mediated gene therapy is strongly
dependent on the proportion of target cells transduced, particu-
larly when trying to halt disease progression in post-mitotic tis-
sues such as the retinal pigment epithelium (RPE), photorecep-
tors, neurones, and myocytes. While transduction can be
increased to some extent by vector dosage, host inflammatory
and immune responses to AAV become limiting factors at
high doses, and they may compromise the persistence of trans-
gene expression and therapeutic effects.10–13 Consequently,
despite promising results seen with retinal gene therapy, cases
of intraocular inflammation have been encountered.14–16 There-
fore, one of the major challenges of gene therapy for retinal dis-
eases is how to achieve sufficient levels of gene replacement at a
safe vector dose.
After initially detecting specific upregulation of a panel of intracel-
lular innate immune factors following AAV retinal gene therapy in
mice, we investigated hydroxychloroquine (HCQ), a putative inhibi-
tor of anti-viral pattern recognition receptors Toll-like receptor 9
(TLR9) and cyclic guanosine monophosphate (GMP)-AMP synthase
(cGAS),17–19 as a means of improving the efficacy of AAV gene ther-
apy. Here we demonstrate the enhancement of AAV transduction
in vitro, ex vivo, and in vivo using HCQ in both murine and human
tissues and specifically within RPE and photoreceptor cells. We inves-
tigated the effect of HCQ across two commonly used serotypes of
AAV, and we assessed its safety and efficacy when co-administered
subretinally with AAV in vivo. Together, these findings suggest that
the adjunctive use of HCQ during AAV gene therapy may provide
a safe means of improving AAV transduction within the retina
in vivo.ical Development Vol. 14 September 2019 ª 2019 The Authors. 77
the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1. Summary of the Anti-viral Functions of Key Intracellular Innate
Immune Mediators
Gene Alias Summary of Function Reference
Tlr9
detects unmethylated CpG DNA within
the cytosol to activate downstream anti-viral
responses
24
Rig-I Ddx58
detects cytosolic viral RNA, including sequences
that have been transcribed by RNA polymerase
III from AT-rich dsDNA
37
Cgas Mb21d1
detects cytosolic dsDNA and synthesizes the
secondary signaling molecule cGAMP
38,39
Sting Tmem173
activated by cGAMP, stimulates TBK1 to
phosphorylate IRF3, which can induce type I
interferon response
40,41
Trim21
detects and neutralizes antibody-bound virions
after endosomal escape
42,43
Ifn-g
type II interferon that controls innate and
adaptive anti-viral immune responses
44
Tnf-a
proinflammatory cytokine that can induce the
breakdown of the blood-retina barrier
25–27
Cxcl10
chemokine secreted in response to IFN-g and
activates leukocytes to regulate immune
responses
45
Isg15
an ubiquitin-like molecule stimulated by type I
interferon in response to viral infection; covalent
and non-covalent binding can disrupt viral
replication
46
Apobec3
deaminates cytidine to uridine in viral DNA,
causing hypermutations that inhibit viral
replication
47
Apobec2
lacks identifiable cytidine deaminase activity
and no known anti-viral activity
48
Aid Aicda
cytidine deaminase involved in immunoglobulin
gene hypermutation and class switching
49
Tlr9, Toll-like receptor 9; Ddx58, DExD/H-Box Helicase 58; Rig-I, retinoic acid-induc-
ible gene 1; Mb21d1, mab-21 domain containing 1; Cgas, cyclic GMP-AMP synthase;
dsDNA, double-stranded DNA; cGAMP, cyclic GMP-AMP; Tmem173, transmembrane
protein 173; Sting, stimulator of interferon genes; TBK1, TANK-binding kinase 1; IRF3,
interferon regulatory factor 3; Trim21, tripartite motif containing 21; Tnf-a, tumor ne-
crosis factor-a; Ifn-g, interferon-g; Cxcl10, C-X-C motif chemokine ligand 10; Isg15,
interferon-stimulated gene 15; Apobec3, apolipoprotein B mRNA-editing enzyme, cat-
alytic polypeptide 3; Aicda, activation-induced cytidine deaminase (Aid).
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AAVRetinal Gene Therapy Activates Intracellular Innate Immune
Responses In Vivo
To assess the activation of innate immune responses to AAV following
retinal gene therapy, we first performed subretinal injections of an
AAV serotype 2 vector encoding GFP driven by a ubiquitous CAG
promoter (AAV2.CAG.GFP) and sham injections of diluent in paired
eyes of 4-week-old female C57BL/6J mice. The purity of the AAV vec-
tor was confirmed during the production process (Figure S1).
Expression of a panel of key anti-viral sensors and effectors (Table 1)
was assessed using qRT-PCR of retinal samples collected on days 3, 7,
and 15 post-injection. Significant upregulation of the intracellular78 Molecular Therapy: Methods & Clinical Development Vol. 14 Septemviral sensors Tlr9, Rig-I (also known as Ddx58), Cgas (Mb21d1), Sting
(Tmem173), and Trim21 (Figure 1A) and anti-viral effectors Ifn-g,
Tnf-a, Cxcl10, Isg1, and Apobec3 (Figure 1B) was detected in eyes
treated with AAV compared to those sham injected with PBS.
Although there was no effect on gene expression soon after gene ther-
apy (3 days post-injection), after 7 days all the viral sensors and effec-
tors were significantly upregulated compared to sham controls, with
Ifn-g, Tnf-a, and Cxcl10 exhibiting >10-fold increases in gene expres-
sion. By day 15, the expression levels of all these genes dropped rela-
tive to day 7, with Rig-I, Mb21d1, Ifn-g, Cxcl10, and Isg15 no longer
demonstrating a significant difference from the sham eye. In contrast,
no change in the expressions of Apobec2 and Aid (also known as
Aicda), both members of the same family of cytidine deaminases as
Apobec3, was seen over the 15-day course, suggesting that AAV
induced selective activation of innate immune responses (Figure 1C).
GFP transgene expression was significantly above baseline from day 7
onward (one-way ANOVA, p = 0.0003; n = 5–7) (Figure S2).
The Antimalarial Drugs HCQ and Chloroquine Can Increase AAV
Transduction in Mouse Embryonic Fibroblasts
Since the activation of proinflammatory cytokines could create an
anti-viral environment within the target tissue, thus restricting
AAV transgene expression and persistence, we postulated that the
suppression of intracellular immunity might enhance the efficacy of
AAV transduction. We identified HCQ as a putative inhibitor of
two key sentinels in the initiation of intracellular anti-DNA viral
response: cGAS, which detects the presence of cytosolic double-
stranded DNA (dsDNA),17 such as inverted terminal repeats (ITRs)
that form secondary structures in single-stranded AAV genomes;
and TLR9, which detects unmethylated CpG sequences,18,20 also pre-
sent in AAV ITRs.
In an initial dose-escalation trial, wild-type mouse embryonic fibro-
blasts (MEFs) were treated with increasing concentrations of HCQ
up to 50 mM for 1 h prior to transduction with AAV2.GFP, followed
by flow cytometry analysis of GFP fluorescence on day 3. HCQ treat-
ment increased the number of GFP-positive cells up to 18.75 mM;
however, concentrations greater than 18.75 mM appeared to be cyto-
toxic, as evidenced by an increase in 7-aminoactinomycin D (7-AAD)
staining, which coincided with a decrease in GFP positivity (Fig-
ure 2A). Subsequent in-depth testing of HCQ was limited to 3.13-
and 18.75-mM concentrations. The mean proportion of GFP-positive
cells increased in a dose-dependent manner from 6% with no HCQ to
9% with 3.13 mM HCQ and 19% with 18.75 mM HCQ (one-way
ANOVA, p = 0.0026; n = 6), without adverse effects on cell survival
(Figures 2B and 2C).
To see if the enhancement of AAV transduction by HCQ might be a
drug class effect, we also tested the structurally similar 4-aminoquino-
line antimalarial compound chloroquine (CQ). Pre-incubation of
MEFs with CQ for 1 h prior to transduction with AAV2.GFP also
improved transduction from 2.5% with no CQ to 6.4% with 12 mM
CQ (Figure S3). Since HCQ is known to be less retinal toxic than
CQ in patients on long-term therapy for lupus and rheumatoidber 2019
Figure 1. Intracellular Innate Immune Responses Are Activated by AAV
Gene Therapy
AAV2.GFP vector (1  109 gc) was subretinally injected into wild-type C57BL/6
mice, with sham injections of PBS undertaken in the contralateral eye. RNA was
extracted from the mouse retina on days 3, 7, and 15 post-injection (n = 3/time
point). The expressions of a range of cytosolic anti-viral (A) sensor and (B) effector
genes and (C) two genes from the APOBEC family were quantified using qRT-PCR.
Relative expression was calculated as a mean fold change (±SEM) relative to the
mean of both eyes from uninjected baseline controls (n = 2). *p% 0.05, **p% 0.01,
****p% 0.0001 (two-way ANOVA with Sı´da´k’s multiple comparison test).
www.moleculartherapy.org
Molecular Tharthritis,21 we chose 3.13 and 18.75 mM HCQ as the minimum and
maximum effective concentrations of HCQ to move forward for
testing in other in vitro, ex vivo, and in vivo systems.
HCQ Increases AAV Transduction in Non-human Primate RPE
Cells and Human Retina Ex Vivo
To assess the applicability of HCQ augmentation of AAV transduc-
tion in retinal gene therapy, primary RPE cells were isolated from
non-human primate (NHP; rhesus macaque) eyes and immediately
placed into culture. The RPE cells were treated with 0, 3.13, or
18.75 mM HCQ for 1 h prior to transduction with AAV2.GFP. At
3 days post-transduction, GFP expression was visualized by fluores-
cence microscopy and quantified by qRT-PCR and western blot. A
visible increase in GFP fluorescence could be seen in RPE cells treated
with HCQ compared with AAV vector alone (Figure 3A), which
correlated to an up to 3-fold increase in GFP mRNA expression in
cells treated with 18.75 mM HCQ (one-way ANOVA, p = 0.0253;
n = 3 eyes) (Figure 3B). A similar magnitude of increase in GFP pro-
tein expression associated with HCQ was also detected by western
blot; however, this did not reach statistical significance due to limited
NHP tissue availability (n = 2) (Figures 3C and 3D).
Since inherited retinal degenerations can affect both RPE and photore-
ceptor cells, we next tested whether the effect of HCQ on AAV trans-
duction also applied to photoreceptors. To this end, human retinal ex-
plants were collected from patients undergoing routine clinically
indicated retinectomy as part of retinal detachment repair. The retinal
explants were treated with either 0 or 3.13 mM HCQ for 1 h prior to
transduction with AAV2.GFP. GFP fluorescence was visualized using
fluorescence microscopy on days 3, 5, 7, 9, and 11 post-transduction
(Figure 3E), and it was quantified using mean gray values of the ex-
plants imaged under standardized conditions.22 The data from retinal
tissue harvested from two (of two) patients independently showed
consistent trends of increased fluorescence in the explants treated
with HCQ from day 7 onward when significant GFP fluorescence
became detectable. A statistically significant difference was observed
with the treatment effect of HCQ over time (two-way ANOVA, patient
1 p = 0.0002; patient 2 p = 0.0092; n = 3), with amean 2-fold increase in
mean gray value at day 11 for the two patients (Figure 3F).
Co-administration of HCQ with AAV Vector Improves Retinal
Gene Therapy In Vivo without Detectable Toxicity
To assess the translational potential of HCQ to retinal gene therapy,
we tested the effect of co-administration of HCQ with AAV vectorerapy: Methods & Clinical Development Vol. 14 September 2019 79
Figure 2. Hydroxychloroquine (HCQ) Increases AAV Transduction in Mouse Embryonic Fibroblasts (MEFs)
Wild-type MEFs were pre-treated with HCQ for 1 h prior to transduction with AAV2.GFP at an MOI of 1,000. (A) Representative dose-response curve of HCQ concentration
versus either GFP-positive or dead (7-AAD-positive) cells, represented as a percentage of the total number of cells. (B) Representative fluorescence microscopy images of
MEFs treated with 0, 3.13, or 18.75 mMHCQ acquired at 3 days post-transduction (scale bar: 200 mm), shown alongside flow cytometry analyses gated for GFP fluorescence
and the cell viability marker 7-AAD. (C) Proportion of GFP-positive (GFP+) cells expressed as a percentage of the total number of live (7-AAD-negative) cells at day 3. Data are
presented as mean ± SEM (n = 6). *p% 0.05, **p% 0.01 (one-way repeated-measures ANOVA with Dunnett’s multiple comparison test).
Molecular Therapy: Methods & Clinical Developmentin vivo. The 7-week-old female C57BL/6J mice were subretinally in-
jected with 1  108 genome copies (gc) of AAV2.GFP containing
either 3.13 or 18.75 mM HCQ in one eye and AAV vector only in
the fellow eye. The fluorescence of the mouse retina was measured
at regular intervals up to 8 weeks using in vivo confocal scanning laser
ophthalmoscopy (cSLO) at standardized detector sensitivity. Cross-
sectional structure of the retina was also monitored using in vivo spec-
tral domain optical coherence tomography (OCT) to look for signs of
retinal toxicity.
Retinal fluorescence was found to be increased in eyes that received
AAV vector suspension containing 18.75 mM HCQ compared with
paired eyes that received AAV vector alone (Figure 4A). No differ-
ence was seen in eyes that received AAV with 3.13 mM HCQ (Fig-
ure 4B). Although a clear trend in favor of HCQ was visible, the dif-
ferences in mean retinal fluorescence based on normalized gray
value comparisons did not reach statistical significance. This is likely
because the method did not distinguish between the diffuse back-
ground fluorescence (which represents GFP expression) and scat-
tered clumps of hyperfluorescence (representing autofluorescent
macrophage aggregates associated with inflammation). In addition,
the statistical power of the comparison was reduced by the exclusion
of 4 of 13 mice (final n = 5 for 3.13 mM and n = 4 for 18.75 mM) due
to unintended intravitreal injections or subretinal bleed during
surgery.
To more specifically compare levels of GFP protein expression be-
tween the treatment arms, the mouse retinae were harvested for
western blot analysis at the final time point (8 weeks). Eyes that
received AAV with 18.75 mM HCQ showed a mean 4.6-fold increase
in GFP protein level compared with paired eyes that received AAV80 Molecular Therapy: Methods & Clinical Development Vol. 14 Septemvector alone (Wilcoxon matched-pairs signed rank test, p = 0.0034;
n = 12) (Figure 4C). In terms of the safety of HCQ administration
into the subretinal space, in vivo OCT imaging demonstrated no
detectable change in lamellar retinal architecture relating to the
administration of HCQ (Figure 4D). Moreover, there was no signif-
icant difference in the mean retinal thickness of eyes injected with
HCQ compared to paired eyes sham injected with PBS (Figure 4E).
By measuring the mean gray value of the fundus using cSLO, we
demonstrated that there was no significant difference in the auto-
fluorescence of eyes injected with PBS compared to those injected
with HCQ alone, suggesting that HCQ is not autofluorescent
(Figure 4F).
Next, we investigated whether HCQ was able to specifically enhance
transgene expression within photoreceptors in vivo and whether the
effect was applicable to different AAV serotypes. 4- to 5-week-old
129S2/SvHsd mice were subretinally injected with 1  108 gc of an
AAV8(Y733F) serotype vector expressing GFP under the photore-
ceptor-specific promoter G protein-coupled receptor kinase 1
(GRK1) (AAV8(Y773F).GRK1.GFP), with injections of AAV com-
bined with 18.75 mMHCQ performed in the contralateral eye. Retinal
GFP protein expression was found to be 5.9-fold higher in eyes in-
jected with AAV containing 18.75 mM HCQ compared to AAV
only (Wilcoxon matched-pairs signed rank test, p = 0.0391; n = 9)
(Figure 4G).
Mechanism of Action of HCQ
While HCQ is routinely used in the treatment of autoimmune dis-
eases, its exact mechanism of action remains unclear. Several studies
support the main mode of action of HCQ as via inhibition of the
innate immune factors TLR918,20 and cGAS.17ber 2019
Figure 3. HCQ Increases AAV Transduction in Non-human Primate (NHP) Retinal Pigment Epithelium (RPE) Cells and Human Retina
(A–D) Primary macaque RPE cells were treated with 0, 3.13, or 18.75 mM HCQ for 1 h prior to transduction with 2  109 gc AAV2.GFP. (A) Representative fluorescence
microscopy images acquired on day 3 post-transduction (scale bar, 200 mm). (B) Levels ofGFPmRNA in AAV- andHCQ-treated RPE cells were quantified using qRT-PCRon
day 3 post-transduction, and they are expressed as mean fold change relative to cells treated with AAV only (±SEM, n = 3). *p % 0.05 (one-way ANOVA with Dunnett’s
multiple comparison test). (C) Representative western blot of GFP protein expression with b-actin used as a loading control. (D) Quantification of GFP band density normalized
to b-actin. Data are presented as mean ± SEM (n = 2). (E and F) Fresh patient-derived retinal explants were treated ex vivowith 0 or 3.13 mMHCQ for 1 h prior to transduction
with 1 109 gc AAV2.GFP (UK research ethics approval 10/H0505/8). (E) Representative transmission microscopy image at baseline and fluorescence images acquired on
alternate days up to day 11 post-transduction (scale bar, 100 mm). (F) GFP expression was estimated by calculating the mean gray value of fluorescence images from two
separate patients. These were normalized to untransduced controls treated with equivalent concentrations of HCQ. Data are expressed as mean ± SEM (3 replicates/
patient). **p% 0.01, ****p% 0.0001 (two-way repeated-measures ANOVA with Sı´da´k’s multiple comparisons test).
www.moleculartherapy.orgWe first tested the effect of HCQ on AAV transduction in Cgas/
MEFs with the hypothesis that, if HCQ acted via the inhibition of
cGAS, its effect would be diminished in the absence of cGAS. While
we found that Cgas/ MEFs transduced with up to 6.4-fold greater
efficacy than wild-type MEFs at the same MOI (t test, p = 0.0008;
n = 6) (Figure 5A), the addition of HCQ was still able to increase
the mean rate of AAV transduction from 38% with no HCQ to
65% with 3.13 mM HCQ and 74% with 18.75 mM HCQ (one-way
ANOVA, p < 0.0001; n = 6) (Figures 5B and 5C). Consequently, there
was no significant difference in the effects of 18.75 mMHCQ on wild-
type versus Cgas/ MEFs (Figure 5D). This indicates that HCQ is
unlikely to act exclusively via the inhibition of cGAS.Molecular ThNext we explored the role of TLR9 in AAV transduction with the
use of the agonistic TLR9 oligodeoxynucleotide CpG-A,23 which
contains unmethlyated CpG sequences known to stimulate
TLR9 activity.24 Cells were treated with CpG-A for 30 min prior
to AAV2.GFP transduction with or without HCQ, and GFP fluo-
rescence was quantified using flow cytometry 3 days post-trans-
duction. CpG-A treatment significantly reduced the mean number
of GFP-fluorescing cells by 2.7-fold relative to untreated cells
(Figures 6A and 6B) (paired t test, p = 0.0001; n = 7) and by
1.9-fold in HCQ-treated cells (Figures 6C and 6D) (p = 0.0348;
n = 7). Therefore, the inhibitory effect of CpG-A on AAV trans-
duction was significantly reduced by the presence of HCQerapy: Methods & Clinical Development Vol. 14 September 2019 81
Figure 4. HCQ Enhances AAV Transduction of Mouse
Retina In Vivo and Has No Detectable Effect on
Retinal Architecture or Thickness
(A–F) C57BL/6J mice were subretinally injected with
AAV2.GFP vector alone in one eye and co-injected with
either 3.13 or 18.75 mM HCQ in the fellow eye. (A) Repre-
sentative in vivo confocal scanning laser ophthalmoscopy
autofluorescence images of paired eyes at 8 weeks post-
injection. (B) GFP fluorescence levels were estimated using
themean gray values of autofluorescence images. Eyes co-
injected with HCQ were normalized to fellow AAV only-in-
jected eyes at 2, 4, and 8 weeks post-transduction (±SEM;
3.13 mM, n = 5; 18.75 mM, n = 4). (C) Western blot of GFP
protein levels in paired mouse retinae that received either
AAV vector alone () or vector mixed with HCQ (18.75 mM)
(+) at 8 weeks post-injection. b-actin was used as a loading
control. Quantification of western blot GFP band density
normalized to b-actin in paired eyes is shown (n = 12). (D)
Representative spectral domain optical coherence to-
mography images from fellow eyes that received either
PBS or 18.75 mM HCQ, showing normal retina lamellar
architecture. Total retinal thickness was measured at
points marked with an asterisk. (E) Mean total retinal
thickness of points (*) at 2, 4, and 8 weeks post-injection
(±SEM, n = 8). (F) Mean gray value of eyes injected with
18.75 mM HCQ alone normalized to paired PBS-injected
eyes at 2, 4, and 8 weeks post-injection (±SEM, n = 8).
(G) 129S2/SvHsd mice were subretinally injected with
AAV8(Y733F).GRK1.GFP vector alone in one eye and co-
injected with 18.75 mM HCQ in the paired eye. Represen-
tative western blot of GFP protein levels in paired retinae of
two mice, with red and blue colors corresponding to points
on the graph, is shown. Quantification of GFP band density
normalized to b-actin in paired eyes is also shown (n = 9).
*p % 0.05, **p % 0.01 (Wilcoxon matched-pairs signed
rank test).
Molecular Therapy: Methods & Clinical Development(Figure 6E) (Wilcoxon matched-pairs signed rank test, p = 0.0156;
n = 7).
To assess the effect of HCQ on viral entry, we compared the intra-
cellular AAV genome loads up to 1 h post-transduction between
HCQ-treated and untreated wild-type MEFs. No significant differ-
ence in overall intracellular AAV genome copy numbers was de-
tected by qPCR between HCQ-treated and untreated cells (Fig-
ure S4). Further analysis of subcellular localization of AAV
genomes was conducted by cell fractionation followed by qPCR in
HCQ-treated versus untreated wild-type MEFs 24 h post-transduc-
tion. The presence of HCQ was found to alter the subcellular distri-
bution of AAV with a trend toward increased nuclear localization
(two-way ANOVA, p = 0.0356; n = 3) (Figure S5B). However, the ef-
fect did not reach statistical significance upon multiple comparison
testing due to the high level of variation in the qPCR assay. Success-82 Molecular Therapy: Methods & Clinical Development Vol. 14 Septemful separation of cytosolic versus nuclear fractions was confirmed
using the cytosolic marker a-tubulin and nuclear marker histone
H3 (Figure S5A). Genomic glyceraldehyde 3-phosphate dehydroge-
nase (GAPDH) DNA was used as a marker for nuclear DNA
(Figure S5C).
DISCUSSION
Despite AAV vectors being considered to have low immunogenicity,
particularly when administered into the subretinal space, our data
suggest that AAV transduction is associated with the activation of
intracellular innate immunity as well as downstream proinflamma-
tory cytokines independent of surgical trauma. The induction of
Tnf-a, IFN-g, and type I interferon responses could lead to the break-
down of the blood-retina barrier and recruitment of adaptive immu-
nity.25–27 This occurrence would ultimately cause localized tissue
inflammation and reduced therapeutic efficacy, and it may underlieber 2019
Figure 5. Cgas–/– MEFs Transduce Significantly
Better Than Wild-Type Cells, and HCQ Further
Enhances AAV Transduction in Cgas–/– MEFs
MEFs were transduced with AAV2.GFP at an MOI of
1,000. GFP fluorescence and cell viability (7-AAD staining)
were assessed on day 3 post-transduction by flow cy-
tometry. The mean proportion of GFP-positive (GFP+)
cells was expressed as a percentage of the total number
of live (7-AAD-negative) cells. (A) Mean proportion of
GFP+ cells in wild-type and Cgas/ MEFs after trans-
duction with the same MOI (±SEM, n = 6). ***p% 0.001
(paired t test). (B) Representative fluorescence images
and flow cytometry plots of Cgas/MEFs treated with 0,
3.13, or 18.75 mM HCQ 1 h prior to transduction (scale
bar: 200 mm). (C) Mean proportion of GFP+ Cgas/ cells
measured using flow cytometry (±SEM, n = 6). ***p %
0.001 (one-way repeated-measures ANOVA with Dun-
nett’s multiple comparison). (D) Fold change of mean
proportion of GFP+ cells treated with 18.75 mM relative to
0 mM HCQ in wild-type and Cgas/ MEFs. Data are
presented as mean ± SEM (n = 6).
www.moleculartherapy.orgthe cases of intraocular inflammation encountered in retinal gene
therapy trials.14–16
The upregulation of innate immune mediators detected on day 7
post-subretinal gene therapy in vivo does not rule out the presence
of background levels of pre-existing surveillance innate sensors.
Active AAV particles may be present within the subretinal space
for a prolonged period (e.g., days) during which repeated waves of
viral entry into the host cells may occur. The signaling molecule
generated by activated cGAS, cyclic GMP-AMP (cGAMP) has been
shown to traverse intercellular junctions and cause field effects, which
could account for the delayed peaking of innate immune responses.28
In addition, significant GFP mRNA expression was not seen in vivo
until 7 days post-injection, which corresponds to the induction ofMolecular Therapy: Methods & Clinthe innate immune genes and may also suggest
a delay in the uptake of AAV from the subreti-
nal space. Retinal microglia are resident macro-
phages that play an important role in immune
defense in the eye, and they are capable of de-
tecting viruses and secreting inflammatory cy-
tokines to amplify an inflammatory response.29
As these cells are capable of mounting an anti-
viral response through the activation of
cGAS30 and TLR9,31 we cannot rule out the pos-
sibilities that resident microglia may have been
responsible for the upregulation of the innate
immune factors and that the delay could repre-
sent the activation of resident microglia or
recruitment of lymphocytes.
HCQ is an approved antimalarial drug with a
well-established safety profile. It is a putative in-
hibitor of innate immunity, consistent withknown efficacy in the treatments of autoimmune diseases such as sys-
temic lupus erythematosus and rheumatoid arthritis.19,32 A recent
in silico analysis suggested that HCQ can disrupt dsDNA binding
and the activation of cGAS.17 However, we found that HCQ did
not discriminate in its ability to improve AAV transduction between
wild-type and Cgas/MEFs, which suggests that HCQ is unlikely to
act exclusively through cGAS. Also, although Cgas/ MEFs trans-
duce with 6.4-fold greater efficiency than wild-type MEFs, this does
not necessarily imply that cGAS is the sole limiting factor for AAV
transduction, given that the absence of cGAS is likely to affect the
expression of other intracellular innate immune genes.
Additional studies have proposed that HCQ may act through the in-
hibition of TLR9. One group suggested that HCQ may bind to DNAical Development Vol. 14 September 2019 83
Figure 6. The Agonistic TLR9OligodeoxynucleotideCpG-ADecreases AAVTransduction inWild-TypeMEFs andHas a Significantly Reduced Effect inHCQ-
Treated Cells
Wild-type MEFs were treated with or without CpG-A (754.6 mM) 30 min prior to transduction with AAV2.GFP at an MOI of 1,000. GFP fluorescence and cell viability (7-AAD
staining) were assessed on day 3 post-transduction by flow cytometry. (A) Representative fluorescence images and flow cytometry plots (scale bar, 200 mm). (B) The mean
proportion of GFP-positive (GFP+) cells expressed as a percentage of the total number of live (7-AAD-negative) cells (±SEM, n = 7). ***p% 0.001 (paired t test). (C and D)Wild-
type MEFs were treated with 18.75 mM HCQ 1 h prior to transduction with AAV2.GFP, followed by treatment with or without CpG-A 30 min prior to transduction. (C)
Representative fluorescence images and flow cytometry plots (scale bar, 200 mm). (D) The mean proportion of GFP+ cells (±SEM, n = 7). *p% 0.05 (paired t test). (E) The fold
change of transduced live GFP+ cells treated with CpG-A relative to cells with no CpG-A treatment. Cells were either treated with CpG-A alone or with CpG-A and HCQ
(median ± interquartile range, n = 7). *p% 0.05 (Wilcoxon matched-pairs signed rank test).
Molecular Therapy: Methods & Clinical Developmentand cause conformational changes that prevent the activation of
TLR9,18 while others have suggested that the effect of HCQ on endo-
somal pH can indirectly inhibit TLR9, which is localized within
endosomes and activated by an acidic environment.20 We found
that treatment of wild-type MEFs with a TLR9-activating oligonucle-
otide (CpG-A) caused a 2.7-fold reduction in transgene expression,
suggesting that the stimulation of TLR9-mediated innate immunity
can lead to reduced AAV transduction. HCQ significantly, but
incompletely, abrogated the inhibitory effect of CpG-A on AAV
transduction, suggesting that HCQ may be an antagonist of TLR9.
If HCQ prevents the activation of TLR9 by causing conformational
changes in DNA,18 it is possible that the partial response seen may
be a result of the stoichiometric ratio between HCQ and CpG-A,
such that some unbound CpG-A was able to adversely affect AAV
transduction.
However, the possibility of HCQ acting via alternative targets cannot
be ruled out. Our viral entry assay did not show any notable difference
in AAV viral loads soon after transduction, possibly indicating that84 Molecular Therapy: Methods & Clinical Development Vol. 14 SeptemHCQ does not act by decreasing degradation or by increasing AAV
binding or entry into the target cells. Investigation into the subcellular
localization of AAV revealed a strong trend toward shifting from the
cytosol to the nucleus upon HCQ treatment. This observation is
potentially consistent with evasion of intracellular innate immunity,
and it could account for the increased transgene expression seen
following HCQ treatment. Further work is required to clarify the mo-
lecular mechanism of action of HCQ, and it seems likely that the pro-
posed interactions of HCQ are not mutually exclusive, as the drug
may have multimodal effects.
It should be noted that a previous study using a much higher concen-
tration of CQ (at 100 mM, compared with up to 12 mM in this study)
showed a reduction in AAV2 transduction in a human hepatocellular
carcinoma cell line.33 The difference may be the result of the CQ con-
centrations used, e.g., greater lysosomal acidification at the much
higher drug concentration may inhibit lysosomal escape of AAV par-
ticles. However, since CQ is known to be associated with a far greater
chance of retinal toxicity than HCQ at therapeutic concentrations,ber 2019
www.moleculartherapy.orgsignificant differences in their mechanisms of action and effects on
AAV transduction may exist but are outside the scope of this trans-
lational study.
Our data demonstrate that HCQ is able to increase GFP transgene
expression following AAV transduction in vitro, ex vivo, and in vivo
across a range of species. The data also suggest that HCQ can improve
AAV transduction of both RPE and photoreceptors, two key cell tar-
gets for retinal gene therapy. Subretinal injection of HCQ together
with an AAV vector led to increased transgene expression, which
was sustained up to 8 weeks. This effect was seen with both an
AAV2 and AAV8(Y733F) vector, suggesting HCQ has an effect
across multiple serotypes of AAV commonly used in retinal gene
therapy. Furthermore, we have demonstrated HCQ to work with vec-
tors containing both ubiquitous and photoreceptor-specific pro-
moters, suggesting that adjunctive use of HCQ is capable of increasing
transgene expression levels in photoreceptor cells, which are the pri-
mary target for many retinal degenerations.
While long-term high-dose systemic HCQ therapy is known to
carry a cumulative risk of retinopathies,34 the risk of retinal toxicity
associated with locally administered HCQ was previously unknown.
Our in vivo data indicate that the delivery of a single pulse of
HCQ into the subretinal space was not associated with any retinal
structural change, including preservation of the ellipsoid zone on
the OCT within treated areas, which represents organized photore-
ceptor inner and outer segments up to 8 weeks post-injection.
One of the limitations of the study is that, while HCQ enhanced
retinal gene therapy in the healthy retina of wild-type mice
without any sign of toxicity, it remains to be seen whether the ef-
fects would be the same in the degenerate retina of mouse models
of retinitis pigmentosa, which would provide support for future
clinical application.
The proportion of retinal cells that successfully acquire and maintain
transgene expression determines the clinical efficacy of gene therapy
in neurodegenerative diseases. For X-linked and autosomal recessive
retinitis pigmentosa, which account for approximately 40% of pa-
tients with identified mutations, achieving over 50% photoreceptor
transduction may be seen as a threshold for halting disease progres-
sion, since female carriers of X-linked mutations are usually mini-
mally affected (e.g., choroideremia, X-linked retinitis pigmentosa
associated with mutations in RPGR or RP2). Therefore, a 2-fold in-
crease in transgene expression with the adjunctive use of HCQ has
the potential to push the therapeutic effect beyond the threshold
required to halt disease progression. Alternatively, co-administration
of HCQ with the AAV vector could enable a lower vector dose to be
used to achieve a given therapeutic effect, thus reducing the risk of
inflammation and improving safety for the patient. The approach
is broadly applicable and has the potential to augment the effects
of existing gene therapies under investigation, without the need to
modify the clinical grade vector, an important practical consider-
ation given the prohibitive costs of developing gene therapies for
orphan diseases.Molecular ThMATERIALS AND METHODS
Vector Design
The vector pAAV2.CAG.GFP.WPRE.pA contained a GFP transgene
under control of the ubiquitous CAG promoter with a Woodchuck
hepatitis virus post-transcriptional regulatory element (WPRE)
enhancer. The vector pAAV8(Y733F).GRK1.GFP.pA contained the
reporter GFP under control of a photoreceptor-specific promoter
GRK1. Both vectors were single-stranded AAVs.AAV Production
HEK293T cells were grown in HYPERFlasks (Scientific Laboratory
Supplies) and transfected with a total of 500 mg endotoxin-free
plasmid using polyethylenimine (Sigma-Aldrich). The plasmid
pCAG.GFP.WPRE.pA was co-transfected with pDG (PlasmidFactory)
to package into recombinantAAV serotype 2, and pGRK1.GFP.pAwas
co-transfectedwith pRepCap and pHelper (pDeltaAdF6) for packaging
into AAV serotype 8 Y733F. Then 3 days post-transfection, the cells
were harvested, lysed, and treated with nuclease. The AAV population
was isolated from the cell lysates by ultracentrifugation with an iodixa-
nol gradient and purified using Amicon Ultra-15 100K filter units
(Merck Millipore). The final preparations were washed and collected
in sterile PBS. The purity of the AAV preparations were determined
by SDS-PAGE analysis, followed by staining with EZBlue (Sigma-Al-
drich) (Figure S1), and the titers were determined by qPCR. Lot 1 of
AAV2.CAG.GFP.WPRE was used for Figure 1, lot 3 was used for Fig-
ure S5, and lot 2 was used for all other experiments.Mice
Wild-type C57BL/6J mice (Charles River Laboratories) were main-
tained by the Biomedical Science Division, University of Oxford,
UK. Mice were housed in a 12 h light-dark cycle, with food and water
available ad libitum. All procedures were performed under general
anesthesia. All animal procedures were undertaken in accordance
with the Association for Research in Vision and Ophthalmology
guidelines for the humane use of laboratory animals in ophthalmic
research, and they were approved by local and national ethical and
legal authorities.Subretinal AAV Vector-Mediated Gene Therapy
For assessment of the activation of innate immune factors, 4-week-old
female C57BL/6J mice were subretinally injected with 1.5 mL (1 109
gc) of the vector pAAV2.CAG.GFP.WPRE.pA (AAV2.GFP)35 in the
left eye and sham injected with PBS in the right eye (n = 3/time point).
For GFP expression analysis, mice were injected with 1 108 gc (n = 7/
time point). Two mice (four for GFP expression analysis) were left un-
injected to determine baseline gene expression. Retinas were harvested
at baseline and on days 3, 7, and 15 post-injection.
For assessment of the effect of HCQ in vivo, 7- to 8-week-old female
C57BL/6J mice were subretinally injected with 1.2 mL (1.2  108 gc)
AAV2.GFP, with injections of a suspension of AAV2.GFP with either
3.13 mM (n = 7) or 18.75 mM (n = 6) HCQ performed in the contra-
lateral eye. An additional nine mice were injected with 18.75 mMerapy: Methods & Clinical Development Vol. 14 September 2019 85
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ment the cohort for western blot analysis (n = 13). To assess the
toxicity and autofluorescence of HCQ, 7- to 8-week-old female
C57BL/6J mice were subretinally injected with 1.2 mL 18.75 mM
HCQ, with sham injections of PBS undertaken in the paired eye
(n = 12).
The 4- to 5-week-old 129S2/SvHsd mice were subretinally injected
with 1 mL (1  108 gc) AAV8(Y733F).GRK1.GFP, with injections
of AAV8(Y733F).GRK1.GFP with 18.75 mM HCQ performed in the
paired eye (n = 9).
Cell and Tissue Cultures
MEF cells were cultured in DMEM supplemented with L-glutamine
(2 mM), penicillin (100 U/mL), streptomycin (100 mg/mL), and
10% fetal bovine serum. Cells were maintained at 37C in a humidi-
fied 5% CO2 environment. Wild-type and Cgas
/ MEFs were trans-
duced with AAV2.GFP at an MOI of 1,000. When appropriate, cells
were incubated in media with HCQ or CQ for 1 h prior to transduc-
tion. The cells were cultured in HCQ- or CQ-containing media for
3 days post-transduction, at which point fluorescence and transmis-
sion images were acquired and cells were harvested for flow cytome-
try. TLR9 was activated in wild-type MEFs by pre-treatment with
754.6 mM CpG-A (50-GGGGGACGATCGTCGGGGGG-30) for
30 min prior to transduction with AAV2.GFP. CpG-A was phosphor-
othioated at each base (Integrated DNA Technologies). For assessing
viral entry, cell pellets were washed four times with PBS and harvested
for DNA extraction 0, 10, 30, and 60 min post-transduction. For as-
sessing subcellular localization, cell pellets were washed four times
with PBS, and the cytosolic and nuclear fractions were isolated using
the Cell Fractionation Kit (ab109719, Abcam), according to the man-
ufacturer’s instructions.
Primary NHP RPE cells were derived from rhesus macaque
(M. mullata) eyes collected post-mortem from animals euthanized
for other purposes, provided by the MRC Centre for Macaques
(Porton Down, UK). After enucleation, the cornea and lens were
removed under direct visualization with a surgical microscope. Radial
incisions were made toward the posterior pole to flatten the eyecup.
The retina was removed by blunt dissection, and the remaining eyecup
was placed inmedia and stored on ice until the RPE cells were removed.
RPE cells were detached using 2.5% trypsin, and they were cultured in
advanced DMEM supplemented with L-glutamine (2 mM), penicillin
(100 U/mL), streptomycin (100 mg/mL), and 10% fetal bovine serum.
Cells were maintained at 37C in a humidified 5% CO2 environment.
The RPE cells were incubated in media with 0, 3.13, or 18.75 mM
HCQ for 1 h prior to transduction with AAV2.GFP at 2  109 gc/
well of a 12-well plate (n = 3). The cells were cultured inHCQ-contain-
ingmedia for 3 days post-transduction, atwhich pointfluorescence and
transmission images were acquired and the cells were harvested for
RNA and protein extraction using buffer RLT (QIAGEN).
Fresh human retinal explants were collected from two patients with
informed consent during routine retinal detachment surgery where86 Molecular Therapy: Methods & Clinical Development Vol. 14 Septema retinectomy was clinically indicated, with approval by the UK
National Research Ethics Committee (10/H0505/8). Small retinal
fragments approximately 500 mm in diameter were obtained using
a 23G cutter of a surgical vitrectomy system (Constellation Vision
System, Alcon). Within 1 h of tissue collection, individual retinal
fragments were transferred using a Pasteur pipette into organotypic
culture inserts (Falcon, Corning) within 24-well plates. The retinal
explants were cultured in 500 mL Neurobasal-A medium supple-
mented with L-glutamine (0.8 mM), penicillin (100 U/mL), strepto-
mycin (100 mg/mL), 2% B-27 Supplement, and 1% N-2 Supplement
(Thermo Fisher Scientific). Samples were maintained at 34C in a
humidified 5% CO2 environment. After 24 h, the fragments
were transferred to culture media containing either 0 or 3.13 mM
HCQ for 1 h prior to transduction with AA2.GFP at 1  109 gc/
well (n = 3/patient).
Fluorescence and transmission microscopy images were obtained on
alternate days up to day 11 under standardized conditions. The cul-
ture media were replaced on alternate days with fresh media contain-
ing the same concentration of HCQ. To measure the mean gray value
of an explant, as a surrogate for GFP fluorescence, the area of
unfolded retina was traced on the transmission image and overlaid
onto the fluorescence image in ImageJ (NIH, USA).22,36 To account
for background autofluorescence of the well, the mean gray value of
a 2.54-mm band around the retinal tissue was subtracted from the
mean gray value of the tissue. Normalized gray value was then calcu-
lated by subtracting the mean gray value of untransduced retinal tis-
sue (treated with the same HCQ concentration) to account for any
background autofluorescence of the tissue and drug.
Flow Cytometry
Dissociated cells were fixed in 4%methanol-free paraformaldehyde in
PBS for 15 min at room temperature. The fixative was replaced with
1% BSA in PBS and samples were stored on ice until assessment. Cells
were incubated with the cell viability dye 7-AAD for 5 min in the dark
immediately prior to flow cytometry analysis using a BD LSRFortessa.
Fluorescent light was measured using a blue laser at the band-pass fil-
ter 695 nm/40 mW and 530 nm/30 mW to detect the fluorochromes
of 7-AAD and GFP, respectively. Cells expressing GFP were gated for
using untransduced controls, and dead (7-AAD-positive) cells were
excluded using a dead cell population control prepared by heating
the samples to 60C for 20 min.
qRT-PCR
Total RNA was extracted from mouse retinae and NHP RPE cells us-
ing the RNeasy mini kit (QIAGEN). An additional DNA digestion
step was included for the extraction from NHP RPE cells using the
RNase-free DNase kit (QIAGEN). Buffer RLT lysates were kept
from the NHP RPE cells for protein extraction according to the
manufacturer’s instructions. cDNA was synthesized with an oligonu-
cleotide deoxythymine (dT) primer using the Superscript III Kit
(Invitrogen). qPCR of the mouse retinal cDNA samples was under-
taken using iTaq Universal SYBR Green Mastermix (Bio-Rad) for
Apobec3, Apobec2, and Aicda. qPCR of the other innate immuneber 2019
www.moleculartherapy.orggenes (Tlr9, Mb21d1, Ddx58, Sting, Trim21, Ifn-g, Tnfa, Cxcl10, and
Isg15) was undertaken using TaqMan probes (Thermo Fisher Scien-
tific) and TaqMan Fast Universal PCR Master Mix (Applied Biosci-
ences). qPCR of GFP expression in mouse retinae and NHP RPE cells
was performed using specific TaqMan probes and Fast Universal PCR
Master Mix. Gene expression of all genes was normalized to b-actin
and analyzed according to the 2(DDCt) method.
DNA was extracted using the QIAamp DNA Mini Kit (QIAGEN)
from wild-type MEFs; an additional RNase digest was performed
on the cell fractionation samples. qPCR was performed using GFP
and Gapdh genomic DNA copy number TaqMan probes and Fast
Universal PCR Master Mix.
In Vivo Retinal Imaging
cSLO imaging was performed on anesthetized C57BL/6J mice at 2, 4,
and 8 weeks post-subretinal gene therapy using a 55 lens (Spectralis
HRA, Heidelberg Engineering, Heidelberg, Germany), with a real-
time average process of 25 frames and a standardized signal detector
sensitivity of 70. Fundus autofluorescence imaging was measured
within a ring section with a radius between 350 and 860 pixels
from the optic disc, using the ImageJ software (NIH).36 Animals
were also subject to wide-field OCT (Spectralis HRA, Heidelberg En-
gineering) 2, 4, and 8 weeks post-injection. Mice were scanned using a
55 lens, and 8 radial sections were taken with a real-time average
process of 25 frames. The total retinal thickness was manually
measured 3,700 nm from the optic disc at alternate radial sections us-
ing a calliper. Mice with unintended intravitreal injections, significant
subretinal bleeding, or opacities were excluded from analysis. For the
AAV-injected mice, the number included for final SLO and OCT
analysis was n = 5 for those injected with 3.13 mM HCQ and n = 4
for mice injected with 18.75 mM HCQ, and for western blot analysis
the number included was n = 12. For mice injected with HCQ only in
the toxicity study, the final cohort size was n = 8.
Western Blot Analysis
Mouse retinae were lysed in radioimmunoprecipitation (RIPA) buffer
supplemented with protease inhibitors (PIs) and homogenized using
a hand-held homogenizer. NHP RPE protein lysates extracted from
buffer RLT (QIAGEN) were resuspended in 1% SDS. For confirma-
tion of the isolation of cytosolic versus nuclear fractions, PI was added
to Buffer A (ab109719, Abcam) before cell fractionation. Cytosolic
proteins were lysed in Buffer A and nuclear proteins were lysed in
RIPA buffer supplemented with PI.
Protein concentration was measured using a bicinchoninic assay
(Thermo Fisher Scientific). Protein samples were separated using
SDS-PAGE on a 10% or 4%–20% (for Figure S5A) Criterion TGX
Precast gel (Bio-Rad), and they were transferred to a polyvinylidene
difluoride membrane using the TransBlot Turbo system (Bio-Rad).
Membranes were blocked in 3% BSA in PBS + 0.1% Tween-20 prior
to incubation for 1 h with anti-GFP (ab32146, Abcam) or anti-b-actin
(AM4302, Thermo Fisher Scientific) monoclonal primary antibodies.
Cell fractionation membranes were blocked in 5% donkey serum inMolecular ThTris-buffered saline + 0.1% Tween-20 prior to incubation with anti-
histone H3 (ab7291, Abcam) and anti-a-tubulin (ab1791, Abcam)
antibodies. After washing in buffer, GFP- and b-actin-probed mem-
branes were incubated with a corresponding horseradish peroxidase-
conjugated secondary antibody for 30 min (Abcam) and developed
using Clarity ECL (Bio-Rad). Histone H3- and a-tubulin-probed
membranes were incubated with corresponding IRDye secondary an-
tibodies (LI-COR Biosciences). Membranes were detected using the
Odyssey Imaging System (LI-COR Biosciences). Protein band den-
sities were quantified using the ImageStudio Lite software (LI-COR
Biosciences).
Statistical Analysis
All statistical analysis was performed on GraphPad Prism 7.00. Data-
sets that were normally distributed were analyzed using a parametric
test (t test or ANOVA). Data were assessed for equal variance using
the Brown-Forsythe test. Data that were skewed or had an unequal
variance were analyzed using a non-parametric test (Wilcoxon signed
rank test). Multiple comparison corrections were performed using a
Dunnett or Sídák’s test for a one- or two-way ANOVA, respectively.
Paired data were handled accordingly. All statistical tests were per-
formed using an alpha level of 0.05 and using two-tailed testing.
The n and p values are indicated in the figure legends where appro-
priate. Data are presented as mean ± SEM.
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